Skip to main content
Premium Trial:

Request an Annual Quote

AACR: Love and Confusion with Biomarkers

In a panel discussion at the American Association for Cancer Research's annual meeting, Anna Barker, deputy director of the National Cancer Institute, expressed both feelings of love and confusion with biomarkers. "Biomarkers are kind of in the eye of the beholder," she told attendees. "Biomarkers are promising, but they have limitations right now, in terms of what we [as researchers] believe biomarkers to be, and, for example, what the regulators might think they are." Biomarkers, Barker explained, are not the same as diagnostics — biomarkers intended for clinical use must be qualified and validated under Food and Drug Administration rules, whereas diagnostic tests can be cleared by the FDA's Center for Devices and Radiological Health with data supporting their satisfactory analytical and clinical performance. As such, she said, one validated biomarker could potentially translate into many commercially available tests. "You can have a diagnostic that is not qualified as a biomarker, so it's a little confusing right now," Barker said. "One of the things that we all have to think about is when you're developing a biomarker, is it a biomarker or is it a test? It turns out that those are not the same thing — at least not if you're going to go after regulatory approval." The FDA qualifies biomarkers with data supporting a specific context of use, Barker said, which the agency terms "fitness for purpose." This FDA definition has evolved over the last three years, and it has been "confusing to people," she added. Still, Barker has hope for biomarkers as cancer diagnostics. "We love proteins, and we think they're going to be great biomarkers, but we don't have very many. We love nucleic acids and genes as biomarkers — and some of those are doing some interesting things right now in trials," she said. "So, the potential for biomarkers is vast, that's why we have so much interest — we have so many meetings, we talk about them pretty incessantly."

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.